News

Liz Klein Ph.D, MPH, Ohio State CTSI leadership member, co-authored a recent study that found that quitline coaching significantly helped young adults who vape quit.

 This initiative provides training opportunities at both NCATS and FDA.

Due to the size and complexity of Ohio State’s portfolio of more than 7000 active IRB studies, the transition from Buck-IRB to Huron will occur in phases.

Julie Johnson, PharmD, presented about our UM1 Pilot Program.

Are you aware of these changes from the NIH for 2025 applications and reviews? 

In 1976, at a moment in history when U.S. enrollment of women in medical schools had just climbed to 20%, it is notable that the chronicles of the Association of Clinical Research Professionals (ACRP) describe the first meeting of two nurses who were among the field’s earliest clinical research coordinators, Sarah Boyer and Anne LeSher, as the impetus for the formation of the Association. 

The drug development process is a collaborative effort among scientists, patients, industry sponsors, the FDA and healthcare providers.

The National Institutes of Health (NIH) has introduced key policy updates that will impact grant applications, peer reviews and post-award processes. 

The Ohio State University Clinical and Translational Science Institute (CTSI) is seeking reviewers for the Clinical and Translational Science Research Program and the Clinical and Translational Science Pilot Program.